Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | CCR8 | P51685 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28264205 | 0.98 | PRKCI (0.54) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL3986970 | 0.83 | PRKCI (0.49) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL11886372 | 0.80 | PRKCI (0.53) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL30457761 | 0.80 | PRKCI (0.53) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL787084 | 0.79 | PRKCI (0.51) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL5163461 | 0.78 | KDM4E (0.50) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL15436293 | 0.76 | KDM4E (0.48) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL858806 | 0.74 | KDM4E (0.72) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL12853975 | 0.72 | KDM4E (0.68) | PRKCIKDM4ELMNACCR1CCR5 | |
| SCHEMBL22881677 | 0.72 | KDM4E (0.68) | PRKCIKDM4ELMNACCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-109790461-B | Mixture, composition and organic electronic device | 广州华睿光电材料有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3802528-B1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
| EP-3941477-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC Immune SA (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113453688-A | Novel compounds for treating, reducing or preventing conditions associated with Tau aggregates | AC免疫有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2021-07-15 | — | — | US | disclosed |
| EP-3802528-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC Immune SA (CH) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233745-A1 | NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2295428-A2 | Linear pyridazine and pyrrolic compounds, methods of preparation and applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2061785-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008012441-A2 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | PRKCI 2187/4885KDM4E 3850/4885LMNA 2285/4885 |
| US-20210214371-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | PRKCI 1703/4885KDM4E 4066/4885LMNA 2338/4885 |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | PRKCI 1703/4885KDM4E 4066/4885LMNA 2338/4885 |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | PRKCI 1703/4885KDM4E 4066/4885LMNA 2338/4885 |
| US-20100004443-A1 | LINEAR PYRIDAZINE AND PYRROLE COMPOUNDS, METHOD FOR OBTAINING THEM AND APPLICATIONS | PPOX, PNPO, PLPBP | PRKCI 2375/4885KDM4E 2135/4885LMNA 3500/4885 |
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | PRKCI 168/4885KDM4E 1192/4885LMNA 3834/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | PRKCI 1884/4885KDM4E 4065/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.